Lifeboat Foundation

Dowload the pdf

Cannabis sativa, especially one high in the anti-inflammatory cannabinoid cannabidiol (CBD), has been proposed to modulate gene expression and inflammation and harbour anti-cancer and anti-inflammatory properties. Working under the Health Canada research license, we have developed over 800 new Cannabis sativa lines and extracts and hypothesized that high-CBD C. sativa extracts may be used to modulate ACE2 expression in COVID-19 target tissues. Screening C. sativa extracts using artificial human 3D models of oral, airway, and intestinal tissues, we identified 13 high CBD C. sativa extracts that modulate ACE2 gene expression and ACE2 protein levels. Our initial data suggest that some C. sativa extract down-regulate serine protease TMPRSS2, another critical protein required for SARS-CoV2 entry into host cells.

While our most effective extracts require further large-scale validation, our study is crucial for the future analysis of the effects of medical cannabis on COVID-19. The extracts of our most successful and novel high CBD C. sativa lines, pending further investigation, may become a useful and safe addition to the treatment of COVID-19 as an adjunct therapy. They can be used to develop easy-to-use preventative treatments in the form of mouthwash and throat gargle products for both clinical and at-home use. Such products ought to be tested for their potential to decrease viral entry via the oral mucosa. Given the current dire and rapidly evolving epidemiological situation, every possible therapeutic opportunity and avenue must be considered.

Continue reading “In Search of Preventative Strategies: Novel Anti-Inflammatory High-CBD Cannabis Sativa Extracts Modulate ACE2 Expression in COVID-19 Gateway Tissues” »

Coronavirus Success Story: How Rwanda Is Curbing COVID-19 : Goats and Soda They’ve got roughly the same population. But Ohio has over 1,000 new cases a day while Rwanda has had 1,500 cases … since March. Among its strategies: free random testing and robot caregivers.

If you are interested in brain computer interfaces (BCI), then you need to listen to this very exciting podcast!

I have only been aware of this DARPA NNN (Next-generation Non-surgical Neurotechnology) program since mid-March, and it is my number one topic of interest. I am interested in it because I have a plan for mind uploading to extend my life indefinitely — otherwise known as superlongevity in our group — but I have no interest in allowing anyone to drill holes in my head! DARPA is looking at ways for non-invasive methods of connecting the thoughts in our brains to computers. Over time, this could be a method to capture the thoughts and memories and emotions within my mind and transfer them into a computer substrate. And, to be clear, this mind upload will, in fact, be me.

Continue reading “Brain Computer Interfaces Developed by DARPA, US Department of Defense” »

Roche’s Actemra failed to meet its primary and secondary endpoints in a late-stage study involving hospitalized patients with severe COVID-19 associated pneumonia. The drug also failed to hit a key secondary endpoint of reduced patient mortality.

Genentech, the South San Francisco-based Roche subsidiary, launched the Phase III COVACTA study of Actemra, a rheumatoid arthritis drug, in March for this indication. The COVACTA study marked the first global study of Actemra (tocilizumab) plus standard-of-care in this setting. Actemra is an IL-6 inhibitor. The IL-6 protein triggers the body’s immune and inflammatory response to fight infections. But, in the case of those patients where their immune system overreacts, such as in some COVID-19 patients, inhibiting IL-6 could keep the body from attacking itself.

This morning, Genentech announced that COVACTA did not meet its primary endpoint of improved clinical status in hospitalized adult patients with severe COVID-19 associated pneumonia. In addition, the key secondary endpoints, which included the difference in patient mortality at week four, were not met. However, there was a positive trend in time to hospital discharge in patients treated with Actemra, the company said. The median time to discharge for Actemra patients was 20 days, compared to 28 days for placebo patients. Genentech did say, however, that the difference cannot be considered statistically significant as the primary endpoint of the COVACTA study was not met.

When the Shewanella oneidensis bacterium “breathes” in certain metal and sulfur compounds anaerobically, the way an aerobic organism would process oxygen, it produces materials that could be used to enhance electronics, electrochemical energy storage, and drug-delivery devices.

The ability of this bacterium to produce molybdenum disulfide—a material that is able to transfer electrons easily, like graphene—is the focus of research published in Biointerphases by a team of engineers from Rensselaer Polytechnic Institute.

“This has some serious potential if we can understand this process and control aspects of how the bacteria are making these and other materials,” said Shayla Sawyer, an associate professor of electrical, computer, and systems engineering at Rensselaer.

Through a cross-species study of metformin, a common drug used to treat Type 2 diabetes, a team of researchers and clinicians from the Donnelly Center and The Hospital for Sick Children (SickKids) has shown that it could one day be possible to repair brain injury using resident cells in the brain.

“No one’s actually shown before that you can take a drug where there’s a known mechanism on endogenous stem cells and demonstrate that it’s even possible to induce brain growth and positive recovery,” says Donald Mabbott, Program Head and Senior Scientist in the Neurosciences & Mental Health program at SickKids, and co-author of a study published in Nature Medicine on July 27.

Mabbott says metformin is a potential game-changer in terms of how childhood brain injury is treated.

This sucks.

Per- and polyfluoroalkyl substances (PFAS), found in many household products and food packages, have raised concerns because of their persistence and possible toxicity to people and wildlife. Because the compounds don’t break down naturally, they have become environmental contaminants. Now, researchers reporting in Environmental Science & Technology have studied the transport of 29 PFAS into and out of the Arctic Ocean, detecting a newer compound for the first time in Arctic seawater.

After studies indicated that two PFAS—PFOA and PFOS—can cause cancer, a compromised immune response and other health problems in lab animals, the two compounds were voluntarily phased out by industry. However, these legacy compounds are still widely detected in the environment. Intended as a safer replacement for PFOA, HFPO-DA (sold under the trade name GenX) is now thought to pose similar health and persistence concerns. Hanna Joerss and colleagues wanted to investigate the long-range, oceanic transport of legacy and replacement PFAS to the Arctic Ocean—a remote body of water connected to the Atlantic Ocean by the Fram Strait, which is located between Svalbard and Greenland.

Continue reading “Newer PFAS compound detected for first time in Arctic seawater” »

Summary: First responders at the World Trade Center have reduced cortical gray matter thickness, which was consistent with neurodegenerative conditions and evidence their brain age is, on average, ten years older than those of similar ages in the general population.

Source: Stony Brook University

Two studies led by Stony Brook University researchers to be presented virtually at the Alzheimer’s Association International Conference on July 28, 2020, indicate that World Trade Center (WTC) first responders are at risk for developing dementia. The studies included individuals with signs of cognitive impairment (CI) who show neuroradiological abnormalities and changes in their blood similar to that seen in Alzheimer’s disease patients and those with related dementias.

AMID rising global numbers of daily coronavirus infections, a fresh flush of vaccine trial results is offering hope for the longer run.

There are more than 160 coronavirus vaccines in development around the world. About 140 of these are at the preclinical stage, meaning they are still being looked at in laboratories and in animal tests. Another 25 are already being tested in people.